This article relies largely or entirely on a single source. Relevant discussion may be found on the talk page. Please help improve this articlebyintroducing citations to additional sources.
Find sources: "Methylenedioxyallylamphetamine" – news · newspapers · books · scholar · JSTOR (October 2017) |
Names | |
---|---|
Preferred IUPAC name
N-[1-(2H-1,3-Benzodioxol-5-yl)propan-2-yl]prop-2-en-1-amine | |
Identifiers | |
3D model (JSmol) |
|
ChemSpider |
|
PubChem CID |
|
UNII | |
CompTox Dashboard (EPA) |
|
| |
| |
Properties | |
C13H17NO2 | |
Molar mass | 219.284 g·mol−1 |
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa). |
Methylenedioxyallylamphetamine (MDALor3,4-methylenedioxy-N-allylamphetamine) is a lesser-known psychedelic drug. It is also the N-allyl derivativeof3,4-methylenedioxyamphetamine (MDA). MDAL was first synthesized by Alexander Shulgin. In his book PiHKAL, the minimum dosage is listed as 180 mg, and the duration unknown.[1] MDAL produces few to no effects on its own, but may enhance the effects of LSD. Very little data exists about the pharmacological properties, metabolism, and toxicity of MDAL.
This substance is a Class A drug in the Drugs controlled by the UK Misuse of Drugs Act.[2]
This psychoactive drug-related article is a stub. You can help Wikipedia by expanding it. |